

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Balance Sheet

As at 31st Mar	Notes No	2015	2015	2014	2014
		CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>I. EQUITY AND LIABILITIES</b>					
<b>Shareholders' Funds</b>					
Share capital	2	50,000	2,452	50,000	2,452
Reserves & surplus	3	94,186	4,617	60,428	3,541
		144,186	7,069	110,428	5,993
<b>Current liabilities</b>					
Trade payables	4	4,377	215	43,878	2,381
Other current liabilities	5	65,534	3,213	248,532	13,488
Short-term provisions	6	15,269	749	2,847	155
		85,179	4,176	295,257	16,024
<b>Total</b>					
		<b>229,365</b>	<b>11,246</b>	<b>405,685</b>	<b>22,017</b>
<b>Current assets</b>					
Trade receivables	7	-	-	164,313	8,917
Cash & bank balances	8	229,365	11,246	241,372	13,099
		229,365	11,246	405,685	22,017
<b>Total</b>		<b>229,365</b>	<b>11,246</b>	<b>405,685</b>	<b>22,017</b>

**Prakash C Bisht**

CFO (Ingredients) & Sr. VP (Group Accounts)

Place: Noida

Date: 07 May, 2015

**JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC**  
**Statement of Profit and Loss**

For the year ended 31st March,	Notes No	2015		2014	
		CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>REVENUE</b>					
Revenue from operations	9	154,155	7,763	74,800	4,290
Other income	10	316	17	-	-
<b>Total revenue</b>		<b>154,471</b>	<b>7,781</b>	<b>74,800</b>	<b>4,290</b>
<b>EXPENSES</b>					
Finance costs	11	-	-	148	8
Other expenses	12	98,705	5,416	62,108	3,583
<b>Total expenses</b>		<b>98,705</b>	<b>5,416</b>	<b>62,257</b>	<b>3,591</b>
<b>Profit before exceptional items and tax</b>		<b>55,766</b>	<b>2,364</b>	<b>12,543</b>	<b>699</b>
Exceptional items	13	9,587	491	1,960	115
<b>Profit before tax</b>		<b>46,179</b>	<b>1,873</b>	<b>10,583</b>	<b>584</b>
Tax expenses:					
- Current tax		12,422	626	2,934	165
- Deferred tax charge/(credit)		-	-	-	-
		<b>12,422</b>	<b>626</b>	<b>2,934</b>	<b>165</b>
<b>Profit for the Year</b>		<b>33,757</b>	<b>1,248</b>	<b>7,649</b>	<b>419</b>

**Prakash C Bisht**

CFO (Ingredients) & Sr. VP (Group Accounts)

Place: Noida

Date: 07 May, 2015

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC  
Cash flow Statement for the Year Ended

Particulars	31-Mar-15		31-Mar-14	
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>Cash flows from operating activities</b>				
Net Profit/(Loss) before tax	46,179	1,873	10,583	584
<b>Adjustments to reconcile net income to net cash provided by operating activities</b>				
Finance costs	-	-	148	8
	-	-	148	8
<b>Operating profit before working capital changes</b>	<b>46,179</b>	<b>1,873</b>	<b>10,731</b>	<b>592</b>
Adjustments for :				
(Increase)/Decrease in trade and other receivables	164,313	8,829	(40,918)	(2,347)
Increase/(Decrease) in trade and other payables	(222,499)	(11,955)	155,311	8,910
	<b>(12,007)</b>	<b>(1,253)</b>	<b>125,124</b>	<b>7,154</b>
<b>Cash generated from operations</b>				
Direct taxes paid (net of refunds)	-	-	(6,078)	(349)
Interest paid	-	-	(148)	(9)
<b>Net cash inflow/(outflow) in course of operating activities</b>	<b>(12,007)</b>	<b>(1,253)</b>	<b>118,898</b>	<b>6,797</b>
<b>B. Cash flow arising from investing activities :</b>				
<b>Net cash inflow/(outflow) in course of investing activities</b>	-	-	-	-
<b>C. Cash flow arising from financing activities :</b>				
<b>Net cash inflow/(outflow) in course of financing activities</b>	-	-	-	-
<b>D. Foreign currency translation difference</b>		(600)		(243)
<b>Net Increase in cash &amp; cash equivalents (A+B+C)</b>	<b>(12,007)</b>	<b>(1,853)</b>	<b>118,898</b>	<b>6,554</b>
Add: cash & cash equivalents at the beginning of year	241,372	13,099	122,475	6,545
Adjustment: cash & cash equivalents on account of scheme of amalgamation & demerger				
<b>Cash &amp; cash equivalents at the close of the year</b>	<b>229,365</b>	<b>11,246</b>	<b>241,372</b>	<b>13,099</b>

Notes:

- 1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".
- 2) Amounts in brackets are for cash outflows

**Prakash C Bisht**

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date: 07 May, 2015

**JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC**
**Notes to the Financial Statements**

As at 31st Mar	2015		2014	
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>2. SHARE CAPITAL</b>				
<b>Authorized</b>				
	-	-	-	-
	-	-	-	-
	-	-	-	-
<b>Issued, Subscribed and Paid up</b>				
50,000 Equity Shares of CAD 1 Each	50,000	2,452	50,000	2,452
(Previous Year 50,000 Equity Shares of CAD 1 each)	-	-	-	-
	<b>50,000</b>	<b>2,452</b>	<b>50,000</b>	<b>2,452</b>
<b>3. RESERVES AND SURPLUS</b>				
<b>Foreign Currency Translation Reserve</b>				
Foreign Currency Translation Reserve Opening	-	487	-	-
Foreign Currency Translation Reserve During the Year	-	(171)	-	487
	-	<b>315</b>	-	<b>487</b>
<b>Surplus as per Statement of Profit and Loss</b>				
As per last Balance Sheet	60,429	3,054	52,779	2,635
Add: Net Profit after tax transferred from Statement of Profit and Loss	33,757	1,248	7,649	419
Amount available for appropriation	<b>94,186</b>	<b>4,302</b>	<b>60,428</b>	<b>3,054</b>
<b>Total reserve and surplus</b>	<b>94,186</b>	<b>4,617</b>	<b>60,428</b>	<b>3,541</b>
<b>4. TRADE PAYABLES</b>				
Trade payables-due to micro,small and medium enterprises under MSMED Act,2006	-	-	-	-
Trade payables-others	4,377	215	43,878	2,381
	<b>4,377</b>	<b>215</b>	<b>43,878</b>	<b>2,381</b>
<b>5. OTHER CURRENT LIABILITIES</b>				
Income received in advance/unearned revenue	63,034	3,091	217,189	11,787
Statutory dues	-	-	28,843	1,565
Other payables	2,500	123	2,500	136
	<b>65,534</b>	<b>3,213</b>	<b>248,532</b>	<b>13,488</b>
<b>6. SHORT TERM PROVISIONS</b>				
Provision for income tax & wealth tax	15,269	749	2,847	155
	<b>15,269</b>	<b>749</b>	<b>2,847</b>	<b>155</b>

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>7. TRADE RECEIVABLES</b>				
<b>Unsecured,considered good unless stated otherwise Outstanding for period exceeding six months from the date they are due for payment</b>				
Secured,considered good	-	-	-	-
Unsecured,considered good	-	-	-	-
Doubtful	-	-	-	-
Provision for doubtful receivables	-	-	-	-
-	-	-	-	-
<b>Other receivables</b>	-	-	-	-
Secured,considered good	-	-	-	-
Unsecured,considered good	-	-	164,313	8,917
Doubtful	-	-	-	-
Provision for doubtful receivables	-	-	164,313	8,917
-	-	-	-	-
-	-	-	164,313	8,917
-	-	-	<b>164,313</b>	<b>8,917</b>
<b>8. CASH AND BANK BALANCES</b>				
<b>Cash and cash equivalents</b>				
<b>Balances with banks:</b>				
- On current accounts	229,365	11,246	241,372	13,099
	<b>229,365</b>	<b>11,246</b>	<b>241,372</b>	<b>13,099</b>

JUBILANT DRUG DISCOVERY AND DEVELOPMENT SERVICES INC

Notes to the Financial Statements

For the year ended 31st March,	2015		2014	
	CAD	INR (' In Thousands)	CAD	INR (' In Thousands)
<b>9. REVENUE FROM OPERATIONS</b>				
Sales of services	154,155	7,763	74,800	4,290
<b>Revenue from operations</b>	<b>154,155</b>	<b>7,763</b>	<b>74,800</b>	<b>4,290</b>
<b>10. OTHER INCOME</b>				
Other non-operating income	316	17	-	-
	<b>316</b>	<b>17</b>	-	-
<b>11. FINANCE COSTS</b>				
Interest expense	-	-	-	-
Other borrowings cost	-	-	148	8
	-	-	<b>148</b>	<b>8</b>
<b>12. OTHER EXPENSE</b>				
Processing charges	89,624	4,941	49,311	2,838
Rates & taxes	-	-	5,138	294
Legal , professional & consultancy charges	7,961	416	6,863	405
Bank Charges	1,120	59	796	46
	<b>98,705</b>	<b>5,416</b>	<b>62,108</b>	<b>3,583</b>
<b>13. EXCEPTIONAL ITEMS</b>				
Foreign Exchange Gain/Loss	9,587	491	1,960	115
	<b>9,587</b>	<b>491</b>	<b>1,960</b>	<b>115</b>